Evidence map›Paper›PMID 27544588›Full record

ArticleBioorganic & medicinal chemistry2016

Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

Lauren E Ragle, Dilip J Palanisamy, Margaux J Joe, Rachel S Stein, Derek D Norman, Gabor Tigyi, Daniel L Baker, Abby L Parrill

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lauren E RagleDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
Dilip J PalanisamyDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
Margaux J JoeDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
Rachel S SteinDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
Derek D NormanDepartment of Physiology, University of Tennessee Health Sciences Center, 894 Union Avenue, Memphis, TN 38163, United States.
Gabor TigyiDepartment of Physiology, University of Tennessee Health Sciences Center, 894 Union Avenue, Memphis, TN 38163, United States.
Daniel L BakerDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
Abby L ParrillDepartment of Chemistry, University of Memphis, 3744 Walker Avenue, Memphis, TN 38152, United States.
University of Memphis · USUniversity of Tennessee Health Science Center · US

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
NCI NIH HHS R01 CA092160
6 · The paper itself

Abstract

Autotaxin (ATX) is a ubiquitous ectoenzyme that hydrolyzes lysophosphatidylcholine (LPC) to form the bioactive lipid mediator lysophosphatidic acid (LPA). LPA activates specific G-protein coupled receptors to elicit downstream effects leading to cellular motility, survival, and invasion. Through these pathways, upregulation of ATX is linked to diseases such as cancer and cardiovascular disease. Recent crystal structures confirm that the catalytic domain of ATX contains multiple binding regions including a polar active site, hydrophobic tunnel, and a hydrophobic pocket. This finding is consistent with the promiscuous nature of ATX hydrolysis of multiple and diverse substrates and prior investigations of inhibitor impacts on ATX enzyme kinetics. The current study used virtual screening methods to guide experimental identification and characterization of inhibitors targeting the hydrophobic region of ATX. An initially discovered inhibitor, GRI392104 (IC50 4μM) was used as a lead for synthetic optimization. In total twelve newly synthesized inhibitors of ATX were more potent than GRI392104 and were selective for ATX as they had no effect on other LPC-specific NPP family members or on LPA1-5 GPCR.

Indexed as

AnimalsEnzyme InhibitorsHumansHydrophobic and Hydrophilic InteractionsLysophosphatidylcholinesLysophospholipase DLysophospholipidsMiceMolecular Docking SimulationPhosphoric Diester HydrolasesQuantitative Structure-Activity RelationshipEnzyme Inhibitorslysophosphatidic acidLysophosphatidylcholinesLysophospholipase DLysophospholipidsPhosphoric Diester HydrolasesAutotaxinPharmacophoreStructure–activity relationship

Identifiers

PMID27544588
PMCPMC5023007
OpenAlexW2496751486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.